News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
735,584 Results
Type
Article (41617)
Company Profile (307)
Press Release (693644)
Multimedia
Podcasts (88)
Webinars (20)
Section
Business (207271)
Career Advice (2041)
Deals (35888)
Drug Delivery (126)
Drug Development (82573)
Employer Resources (175)
FDA (16530)
Job Trends (15108)
News (350707)
Policy (32972)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (2600)
Accelerated approval (43)
Adcomms (25)
Allergies (165)
Alliances (50264)
ALS (198)
Alzheimer's disease (1761)
Antibody-drug conjugate (ADC) (395)
Approvals (16878)
Artificial intelligence (614)
Autoimmune disease (238)
Automation (52)
Bankruptcy (362)
Best Places to Work (11737)
BIOSECURE Act (20)
Biosimilars (212)
Biotechnology (205)
Bladder cancer (180)
Brain cancer (67)
Breast cancer (699)
Cancer (5472)
Cardiovascular disease (464)
Career advice (1728)
Career pathing (41)
CAR-T (307)
CDC (54)
Celiac Disease (2)
Cell therapy (816)
Cervical cancer (43)
Clinical research (71299)
Collaboration (1990)
Company closure (4)
Compensation (1320)
Complete response letters (74)
COVID-19 (2741)
CRISPR (100)
C-suite (1037)
Cystic fibrosis (151)
Data (7259)
Decentralized trials (3)
Denatured (26)
Depression (157)
Dermatology (70)
Diabetes (553)
Diagnostics (6874)
Digital health (53)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (304)
Drug pricing (195)
Drug shortages (31)
Duchenne muscular dystrophy (268)
Earnings (92170)
Editorial (63)
Employer branding (22)
Employer resources (154)
Events (120857)
Executive appointments (1063)
FDA (20052)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (32)
Funding (1654)
Gene editing (214)
Generative AI (54)
Gene therapy (659)
GLP-1 (1036)
Government (4725)
Grass and pollen (7)
Guidances (400)
Healthcare (19010)
HIV (77)
Huntington's disease (52)
IgA nephropathy (93)
Immunology and inflammation (277)
Immuno-oncology (86)
Indications (164)
Infectious disease (3069)
Inflammatory bowel disease (202)
Inflation Reduction Act (14)
Influenza (132)
Intellectual property (278)
Interviews (320)
IPO (16844)
IRA (50)
Job creations (3695)
Job search strategy (1439)
JPM (58)
Kidney cancer (18)
Labor market (94)
Layoffs (560)
Leadership (35)
Legal (7978)
Liver cancer (98)
Longevity (30)
Lung cancer (732)
Lymphoma (413)
Machine learning (54)
Management (59)
Manufacturing (962)
MASH (182)
Medical device (13886)
Medtech (13968)
Mergers & acquisitions (20235)
Metabolic disorders (1434)
mRNA (178)
Multiple sclerosis (181)
NASH (17)
Neurodegenerative disease (388)
Neuropsychiatric disorders (97)
Neuroscience (3193)
Neurotech (1)
NextGen: Class of 2026 (6548)
Non-profit (4541)
Now hiring (74)
Obesity (675)
Opinion (279)
Ovarian cancer (196)
Pain (238)
Pancreatic cancer (264)
Parkinson's disease (349)
Partnered (33)
Patents (564)
Patient recruitment (625)
Peanut (60)
People (60087)
Pharmaceutical (70)
Pharmacy benefit managers (32)
Phase 1 (22242)
Phase 2 (31441)
Phase 3 (23292)
Pipeline (7480)
Policy (306)
Postmarket research (2572)
Preclinical (9444)
Press Release (64)
Prostate cancer (281)
Psychedelics (49)
Radiopharmaceuticals (321)
Rare diseases (1007)
Real estate (6051)
Recruiting (71)
Regulatory (25289)
Reports (54)
Research institute (2422)
Resumes & cover letters (353)
Rett syndrome (33)
RNA editing (18)
RSV (88)
Schizophrenia (169)
Series A (271)
Series B (206)
Service/supplier (11)
Sickle cell disease (106)
Special edition (22)
Spinal muscular atrophy (164)
Sponsored (45)
Startups (3673)
State (2)
Stomach cancer (18)
Supply chain (126)
Tariffs (87)
The Weekly (60)
Vaccines (1072)
Venture capital (101)
Weight loss (432)
Women's health (114)
Worklife (20)
Date
Last 7 days (610)
Last 30 days (2379)
Last 365 days (30309)
2026 (9177)
2025 (30429)
2024 (35560)
2023 (40488)
2022 (51640)
2021 (56244)
2020 (54472)
2019 (46904)
2018 (35314)
2017 (32519)
2016 (31953)
2015 (38033)
2014 (31864)
2013 (26784)
2012 (28960)
2011 (29624)
2010 (27684)
Location
Africa (748)
Alabama (96)
Alaska (7)
Arizona (337)
Arkansas (15)
Asia (40505)
Australia (6585)
California (12513)
Canada (3593)
China (1294)
Colorado (541)
Connecticut (544)
Delaware (376)
Europe (88477)
Florida (1909)
Georgia (402)
Hawaii (3)
Idaho (62)
Illinois (994)
India (85)
Indiana (577)
Iowa (22)
Japan (505)
Kansas (129)
Kentucky (46)
Louisiana (39)
Maine (75)
Maryland (1513)
Massachusetts (9014)
Michigan (349)
Minnesota (688)
Mississippi (6)
Missouri (142)
Montana (33)
Nebraska (29)
Nevada (137)
New Hampshire (83)
New Jersey (3344)
New Mexico (29)
New York (3322)
North Carolina (1644)
North Dakota (8)
Northern California (6202)
Ohio (373)
Oklahoma (23)
Oregon (42)
Pennsylvania (2532)
Puerto Rico (29)
Rhode Island (50)
South America (1125)
South Carolina (82)
South Dakota (2)
Southern California (4922)
Tennessee (201)
Texas (1980)
United States (44559)
Utah (376)
Vermont (1)
Virginia (300)
Washington D.C. (80)
Washington State (1022)
West Virginia (4)
Wisconsin (123)
Wyoming (2)
735,584 Results for "ipsen biopharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
Ipsen Pulls Cancer Drug Amid Risk of Secondary Malignancies
Ipsen will withdraw Tazverik’s follicular lymphoma and epithelioid sarcoma indications as emerging data point to an elevated safety risk in patients undergoing treatment.
March 9, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Ipsen announces the availability of its 2025 Universal Registration Document
April 2, 2026
·
5 min read
Press Releases
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR
March 18, 2026
·
7 min read
Press Releases
Ipsen appoints Michelle C. Werner as EVP, President of North America
March 12, 2026
·
7 min read
Press Releases
Ipsen announces that Beech Tree has obtained an exemption from the obligation to submit a public tender offer
April 3, 2026
·
6 min read
Press Releases
Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
March 9, 2026
·
8 min read
Press Releases
Update: Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
March 9, 2026
·
8 min read
Press Releases
GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales
February 12, 2026
·
8 min read
Press Releases
New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS
January 14, 2026
·
10 min read
Press Releases
Ipsen nominates Peter Guenter to its Board of Directors
January 29, 2026
·
6 min read
1 of 73,559
Next
